A different subtype of breast cancer known as HER2-positive is aggressive and overexpressed in the human epidermal growth factor receptor 2 (HER2) gene. The landscape of treatment for this population of breast cancer patients has been transformed throughout time by ground-breaking research that resulted in the creation of HER2-targeted medicines.